Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.58 and traded as high as $0.67. Xtant Medical shares last traded at $0.65, with a volume of 160,806 shares changing hands.
Xtant Medical Price Performance
The firm has a market capitalization of $90.99 million, a P/E ratio of -16.25 and a beta of -0.15. The business has a 50-day moving average of $0.62 and a 200 day moving average of $0.58. The company has a current ratio of 2.47, a quick ratio of 1.16 and a debt-to-equity ratio of 0.46.
Hedge Funds Weigh In On Xtant Medical
A number of large investors have recently modified their holdings of the company. Jane Street Group LLC bought a new position in shares of Xtant Medical in the 2nd quarter worth $26,000. Mink Brook Asset Management LLC increased its position in shares of Xtant Medical by 125.8% during the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company's stock worth $81,000 after acquiring an additional 60,997 shares in the last quarter. Crescent Grove Advisors LLC increased its position in shares of Xtant Medical by 94.3% during the second quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company's stock worth $304,000 after acquiring an additional 200,000 shares in the last quarter. AWM Investment Company Inc. acquired a new position in Xtant Medical during the 2nd quarter valued at about $4,875,000. Finally, Nantahala Capital Management LLC boosted its stake in Xtant Medical by 500.3% during the 2nd quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company's stock valued at $50,543,000 after purchasing an additional 57,000,000 shares during the last quarter. 69.33% of the stock is currently owned by institutional investors.
About Xtant Medical
(
Get Free Report)
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
Featured Articles
Before you consider Xtant Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xtant Medical wasn't on the list.
While Xtant Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
